Charles Smith to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Charles Smith has written about Xenograft Model Antitumor Assays.
Connection Strength
0.387
-
Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Mol Cancer Res. 2015 Dec; 13(12):1591-601.
Score: 0.119
-
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011 Mar 01; 11(5):524-34.
Score: 0.088
-
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs. 2011 Dec; 29(6):1132-42.
Score: 0.083
-
The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther. 2015 Dec; 14(12):2744-52.
Score: 0.030
-
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 01; 12(3):229-38.
Score: 0.023
-
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 01; 12(3):239-51.
Score: 0.023
-
Targeting NF?B mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther. 2011 Apr 01; 11(7):678-89.
Score: 0.022